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Abstract 
In well-resourced settings, reduced circulating maternal free placental growth factor (PlGF) aids 
in either predicting or confirming the diagnosis of preeclampsia, fetal growth restriction, 
stillbirth, preterm birth, and delivery within 14 days of testing when pre-eclampsia is suspected. 
This operational pilot implementation of maternal plasma PlGF in women with suspected 
preeclampsia was conducted in six antenatal clinics in Maputo, Mozambique (six control clinics 
for comparison). The primary outcome was transfer to higher levels of care, following the 
informative PlGF assay. Of antenatal visits, 133/31,993 (0·42%) and 20/33,841 (0·06%) resulted 
in pre-eclampsia-related transfers of care for women attending intervention and control clinics, 
respectively (p < 0·0001). The clinic-to-delivery for women with low PlGF (<100 pg/ml) interval 
was shorter, (vs normal PlGF (median 10 days [IQR 1 - 25] vs 36 [11 - 83], p < 0·0001)). Low PlGF 
was associated with younger maternal age, higher blood pressure, earlier delivery, more 
therapeutic interventions, preterm birth, lower birth weight, and perinatal loss. In addition, 
one-third of hypertensive women with PlGF < 50 pg/ml suffered a stillbirth. In urban 
Mozambican women with symptoms and/or signs suggestive of preeclampsia, low maternal 
plasma PlGF concentrations are associated with increased risks of adverse pregnancy 
outcomes, especially early delivery and stillbirth. Therefore, introducing PlGF into the clinical 
care of women with suspected preeclampsia was associated with increased transfers to higher 
levels of care; low PlGF (<100 pg/ml) was associated with increased maternal and perinatal 
risks. PlGF <50 pg/ml is particularly associated with stillbirth in women with suspected 
preeclampsia. 
Keywords 
Preeclampsia; stillbirth; placental growth factor; diagnostic performance; operations research; 
global health 
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Introduction 
Pregnancy hypertension, especially preeclampsia, remains a significant contributor to adverse 
maternal and perinatal events in sub-Saharan Africa (1;2). Some women whose pregnancies are 
complicated by preeclampsia have evidence of angiogenic factor imbalance, with a surfeit of 
antiangiogenic factors (e.g., soluble fms-like tyrosine kinase-1 (sFlt-1)) and reduced 
proangiogenic factors (e.g., placental growth factor (PlGF)) (3-7).  
Previously, we have confirmed the diagnostic performance of masked plasma PlGF in 
identifying women at increased risk of imminent delivery in clinics in Maputo, Mozambique (8); 
through the identification of pregnancy complications beyond preeclampsia, such as fetal 
growth restriction of placental origin (9). Therefore, we have proposed that PlGF should 
improve the provision of precision medicine to individual women and improve pregnancy 
outcomes for those with preeclampsia or related placenta-mediated complications in all 
settings. Thereby, clinicians in all settings may be better able to triage women with suspected 
complications to optimize the care of those most at risk within stretched health systems.  
After completion of this technical evaluation study, we designed and conducted a pilot 
implementation study in health centers to assess the impact of PlGF in aiding the diagnosis and 
time-of-disease risk stratification of preeclampsia, and, thereby, improving appropriate 
interventions for, and timely care of women with preeclampsia. In contrast to clinical research 
methods, which typically focus on the health effects of an evidence-based practice, 
implementation studies typically focus on rates and quality of use of evidence-based practices 
rather than their effects (10).  
Methods 
Study design and context 
This operational pilot study was conducted with screening and testing of women from 26 April 
to 30 November 2016. In this context, the objective of this operational pilot was to assess the 
probable impact of large-scale implementation of an intervention, PlGF testing, within a health 
system.  
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All sites were in Maputo city, with six intervention sites (CS Bagamoyo, CS Chamanculo, CS Jose 
Macamo, CS Magoanine, CS 1 de Junho, CS 1 de Maio) and six control sites (CS Albazine, CS 
Catembe, CS Polana Canico, CS Pescadores, CS Xipamanine, CS Zimpeto). All sites offered 
prenatal care services, booked approximately 200 newly-identified pregnant women each 
month (i.e, 1400 new pregnancies per site), and had both on-site laboratory support and a 
maternity unit. CS Jose Macamo is associated with a general hospital. One site (CS 1 de Maio) 
has an ultrasound available, and CS Jose Macamo has access to the adjacent hospital’s 
maternity unit ultrasound. The other four sites refer to the general hospital for ultrasounds, 
and any women referred need to use either public transport, car, or walk to get their 
ultrasound. Routine obstetric ultrasound was not offered at any sites, but limited to those 
deemed to be at high risk. Pregnancy dating was based upon last menstrual period and 
symphysis-fundal height. Intervention sites were matched, without randoimization, to control 
sites based on antenatal clinic volume, maternity ward, type of support, electricity and 
laboratory. Referral centers were shared between intervention and control sites. 
Intervention sites 
All pregnant women, irrespective of age, attending the respective prenatal clinics of the six 
intervention sites were screened for hypertension by the attending nurse, and if any given 
pregnant woman <37
+0
 weeks’ pregnant presented with any evidence preeclampsia (i.e., high 
BP, proteinuria, signs or symptoms) she would be a candidate for the PlGF test.  
BP was measured with women sitting and with the right arm supported at the level of the heart 
as part of routine prenatal care, using Microlife BP A2 Basic, (Microlife AG, Widnau, 
Switzerland) fully automated BP monitors. BP measurement was repeated if hypertension 
(defined as either a systolic BP ≥ 140 mm Hg or a diastolic BP ≥ 90 mm Hg) was detected on the 
first reading and the lower reading recorded in the data collection form. Normotensive readings 
were not repeated. The presence of significant proteinuria (≥2+ by dipstick) was not an 
eligibility criterion.  
At the time of the prenatal visit that triggered eligibility (suspected preeclampsia), venous 
blood was collected by the clinic nurse, plasma prepared, and PlGF assayed using the Alere 
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Triage® monoclonal antibody-based immunoassay and meter (Alere, San Diego, CA), according 
to the manufacturer’s instructions by the on-site laboratory technician. Maternal plasma PlGF 
concentrations were quantified within the measurable range of the assay (12 – 3000 pg/ml) and 
classified as either normal (≥100 pg/ml) or low (<100 pg/ml), as determined in our initial study 
(5). Clinical and research staff were not blinded to the PlGF results.  
Pregnant women with suspected preeclampsia remained on site until the PlGF result was 
available and the nurse could use the result to complement diagnosis and determine whether 
or not to initiate a referral. If women were assessed to be too unwell to either await PlGF 
results, or even to have the blood draw, they were referred immediately. On occasion, the 
blood draw was completed, but the transport arrived prior to knowledge of the PlGF result and 
the woman was referred to a tertiary facility without delay. 
Facility management, including delivery decisions, was made by clinicians who were not 
involved in the study and in compliance with Ministry of Health guidelines. The study protocol 
was approved by the National Bioethics Committee in Mozambique. 
Patient information was collected from registries, patient charts and transfer logbooks at the 
prenatal care health facilities and maternity units. Dedicated study assistants were present at 
the intervention sites daily. They were stationed outside the antenatal clinic space and had 
access to all women screened for PlGF, to collect data at the time of screening. In addition, they 
were present when pregnant women returned for later antenatal visits or to the local maternity 
unit for delivery. Retrospective data were collected following delivery for women who delivered 
at referral maternity units. Two study assistants collected data two-to-three times a week to 
follow up transferred women, to ascertain whether or not they had been admitted or delivered, 
and the outcomes of mother and child. They attended the consulting rooms weekly, but did not 
interact with the women; rather, they relied solely on the available paper records (a more 
challenging task at referral facilities). In addition, they went weekly to search for data at referral 
facilities (these sites being the same referral sites for all the health centers). To support data 
collected from registries and patient charts, and fill in potential gaps due to deliveries occurring 
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in the community, pregnant women enrolled in the intervention sites were contacted via either 
telephone or SMS, up to two times within the month after their due date of delivery.  
Control sites 
In the control sites, patient information was collected from registries and transfer logbooks at 
the prenatal care health facilities and maternity units. Two study assistants collected data two-
to-three times a week, and patient chart data, including pregnancy outcomes, were not 
reviewed. 
Outcomes 
The primary outcome for analysis was transfer to higher levels of care, following the 
informative PlGF assay (‘clinic’). Other outcomes of interest included: median time-to-delivery, 
confirmed diagnosis of preeclampsia, mode of delivery, intrauterine fetal death, and preterm 
birth (<37
+0
 weeks). For outcome adjudication, preeclampsia was defined as hypertension and 
either significant proteinuria or other maternal organ dysfunction, according to the 2014 ISSHP 
criteria (11). Adjudication of a diagnosis of preeclampsia was performed by obstetricians not 
involved in the women’s care but taking into consideration the PlGF results. 
Sample size 
The sample size was determined considering that the pilot was a two-arm multi-site 
observational cohort, with six health facilities in each of the intervention and control arms. 
Assuming that PIGF would be able to diagnose about 25% more cases in the intervention sites 
than conventional care in the control sites (above a baseline prevalence of 35% in women with 
suspected preeclampsia in control sites), the sample size required for 80% power and 5% 
significance was 106 in each arm.  
Statistical approach 
Statistical analyses: Kaplan-Meier curves were derived and Mantel-Cox log-rank test survival 
analyses performed to describe the primary outcome. Fisher’s exact and chi-square tests were 
used for categorical variables and Mann-Whitney U tests were used for continuous variables. 
  
8 
 
To assess the performance of PlGF to identify women who suffered an intrauterine fetal death, 
an area under the receiver-operator curve (AUC ROC) analysis was performed. Using Prism 5·0 
(GraphPad, San Diego, CA), statistical significance was set at p<0·05 for the primary comparison, 
and p<0·01 for other comparisons (to adjust for multiple comparisons). 
Results 
During the seven months of the study, the diagnosis of preeclampsia was suspected in 278 and 
194 women in intervention and control sites, respectively. These represent 0·87% of 31,993 and 
0·57% of 33,841 antenatal visits in intervention and control sites, respectively (Yate’s-corrected 
χ
2
 p < 0·0001; relative risk 1·21 (95% confidence interval (CI) 1·13 - 1·31). In addition, this 
represents a 3·3% detection rate (assuming 8400 women receiving prenatal care in the six 
intervention sites), compared with a 2·3% (194/8400 women) suspected preeclampsia rate in 
six control sites (Yate’s-corrected χ
2
 p = 0·0001; relative risk 1·23 (95% CI 1·09 - 1·37)). Fetal 
heart sounds were detected using Pinard stethoscopes in all women at eligibility.  
Maternal transfer to higher levels of care (primary outcome) was initiated for 133/278 (47·8%) 
and 20/194 (10·3%) of women in intervention and control sites, respectively (Yates-corrected χ
2
 
p = 0·0001; relative risk 1·91 (95% CI 1·67 - 2·19)). These represent referral rates of 0·42% and 
0·06% of antenatal visits in intervention and control sites, respectively (Yate’s-corrected χ
2
 p < 
0·0001; relative risk 1·79 (95% CI 1·68 - 1·91). 
Table 1 describes the baseline characteristics and outcomes of the 278 women with suspected 
preeclampsia attending for prenatal care at the intervention sites. Compared with 148 women 
with normal PlGF (≥100pg/ml), the 130 women with low PlGF (<100 pg/ml) were younger, at 
later gestational age when screened for PlGF, more severely hypertensive, more likely to have a 
confirmed diagnosis of preeclampsia by either proteinuria or symptoms, especially 
symptomatic preeclampsia, and more likely to have an increased number of prenatal visits (all p 
<0·01); they tended to be more often nulliparous (p = 0·0180) and receive antihypertensive 
medication (p = 0·0191). This detail of clinical data was not available for the women who 
attended the control sites. 
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In terms of the clinic-to-delivery interval, women with low PlGF delivered more quickly 
(median: 10 days) compared with those with normal PlGF (median: 36 days) (Figure 1(a)). 
Women with low PlGF delivered at earlier gestational ages (35 vs 37 weeks, respectively (Figure 
1(b))), more frequently preterm (85% vs 55%, respectively), and lighter infants (2·5 kg vs 3·1 kg, 
respectively). Only two (0·7%) women in this cohort received antenatal corticosteroids, 
although 117 of 278 (42·1%) women delivered before 35
+0
 weeks of pregnancy. Of the 160 (of 
242 women who received antihypertensive agents) for whom the antihypertensive agents were 
recorded, 33 received solely methyldopa, while three received methyldopa and nifedipine, 100 
received methyldopa and hydralazine and 21 received methyldopa, nifedipine and hydralazine. 
Three women received solely hydralazine. 
There were three maternal deaths, two were women with normal PlGF (one of whom declined 
early referral to hospital and arrived moribund; the other declined to remain an inpatient and 
was lost to local follow-up (moved to South Africa)) and one with low PlGF (in-facility death in 
the regional tertiary hospital). Twenty-three percent of women with low PlGF suffered an 
intrauterine fetal death, compared with 6% of women with normal PlGF (p<0·0001). Neonatal 
survival was similar between groups. 
The area under the receiver-operator curve analysis of the performance determined that 
maternal PlGF predicted both intrauterine fetal death (AUC ROC = 0·78) and perinatal death 
(AUC ROC = 0·75) (Figure 2). Thirty of 30 of 92 (32·6%) women with PlGF <50pg/ml suffered an 
intrauterine fetal death, compared with nine of 177 (5·1%) women with PlGF ≥50pg/ml (Yates-
corrected χ
2
 p<0·0001). Using that cut-off of <50 pg/ml, maternal plasma PlGF has a sensitivity 
of 76·9% (95% CI 60·7% - 88·9%) and specificity of 74·1% (95% CI 68·0% - 79·5%) in the 
prediction of intrauterine fetal death. 
Discussion 
In this implementation study, we have determined that among women with preeclampsia who 
attended prenatal clinics in Maputo, Mozambique, the introduction of a package of care, 
including the use of PlGF, was associated with both an increased detection of preeclampsia and 
an increased number of transfers of care. In addition, low maternal plasma PlGF identified 
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women destined to deliver soon and have more complicated pregnancies, as determined 
previously using masked PlGF results (8). Also, we have determined that maternal plasma PlGF 
<40 - 50 pg/ml identifies a group of women at exceptionally high risk for suffering an 
intrauterine fetal death (32·6% of women with PlGF <50 pg/ml).  
The incidence of suspected preeclampsia in intervention sites was as anticipated from the 
literature (12); it is almost certain that the diagnosis was missed in a number of women in 
control sites. Due to probable incomplete identification of women with suspected preeclampsia 
in the control sites, direct comparison of the performance of the PlGF assay in terms of 
reducing the incidence of preeclampsia-related adverse pregnancy outcomes could not be 
assessed. However, women in the intervention sites were almost twice as likely to be referred 
to higher levels of care than were women in control sites. The identification of women with 
pregnancies complicated by preeclampsia and responding to precision risk assessment using 
PlGF, as achieved in the intervention sites, are critical steps towards reducing direct maternal 
deaths due to pregnancy hypertension (13).  
Incomplete knowledge of the detailed clinical characteristics and outcomes of women who 
attended for prenatal visits in the control sites is the major limitation of this pragmatic 
operational pilot study. In addition, the level of confidence in these results might have been 
improved had a stepped-wedge implementation trial design been used (14). 
The exact threshold for raising specific intrauterine fetal death concern requires specific 
hypothesis-driven research in both general populations and targeted high-risk populations (e.g., 
preeclampsia, fetal growth restriction, previous intrauterine fetal death) of women. If testing 
for maternal PlGF can be converted into a whole blood point-of-care assay, we believe that 
there is great potential for this biomarker of the imperfectly performing placenta to be used at 
scale to reduce the burden of intrauterine fetal death. Currently, in less-developed settings 
without access to sophisticated Doppler ultrasound, we believe that a maternal plasma PlGF 
<50 pg/ml should be considered as a strong indication for initiating delivery. 
Although the median number of prenatal care visits was the same in women with normal and 
low PlGF (median number of visits: 3), there was a significant increase in the number of visits in 
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the low PlGF group as a whole (p=0·0006). This is likely to be due to an appropriate response by 
the woman and her care providers’ knowledge about her low PlGF status, although these low 
PlGF women remained pregnant for about one-third of the time (median: 14 days) than did 
women with normal PlGF (median: 41 days). 
Two hundred and forty-two (87·1%) women with suspected preeclampsia in the intervention 
cohort received antihypertensive agents, with a trend for more in the low PlGF group (p = 
0·0191). This probably reflects higher systolic and diastolic blood pressure readings at the 
recruitment prenatal visit. However, as any severe hypertension confers as much risk to a 
pregnancy as the diagnosis of preeclampsia (15), blood pressure should be normalized in all 
pregnancies complicated by hypertension, using the CHIPS Trial tight control decision algorithm 
(16). In settings such as these, in which all three delays that contribute to maternal death are 
operating, tight control (i.e., targeting a diastolic blood pressure of 85 mm Hg, and responding 
to any systolic blood pressure ≥160 mm Hg) is likely to have benefits beyond those observed in 
the main CHIPS Trial. Four hundred and sixty-three of the 981 women in CHIPS developed 
preeclampsia. The preferential use of methyldopa is consistent with knowledge of availability, 
cost, improved pregnancy outcomes and neurodevelopmental reassurance to seven years of 
age (16-19). 
Although known to be the optimal agent for both the prevention and treatment of eclampsia 
(20-23), there was very low use of magnesium sulfate in this cohort (4·7% of hypertensive 
women overall), even though care providers were informed of the PlGF results, and low PlGF is 
known to identify women at greater risk for adverse events (5;8;9). It is incumbent on those 
introducing such a new package of care to ensure vertical integration of the health system and 
that effective messaging around the new technology crosses all levels of the health system to 
modify caregiving behavior. Unfortunately, we were not able to determine with certainty the 
incidence of eclampsia within the cohort. Therefore, whether or not low PlGF should be a 
specific indication for magnesium sulfate use remains uncertain. 
The low rate of use of antenatal corticosteroids (0·7%) in this cohort of women is consistent 
with the findings in our previous Maputo-based study (8) in which only two of 494 women 
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(0·4%) who delivered prior to 35
+0
 weeks received corticosteroids (data previously 
unpublished). Knowledge of low PlGF status did not change the behavior of care providers 
between the two studies. It should be noted that the Mozambique Ministry of Health has only 
recently actively implemented the use of antenatal corticosteroids for fetal lung maturation 
(train-the-trainers workshop, June 5-7, 2017). In addition, the publication of the ACT cluster-
randomized trial in 2015 (24) may have impeded corticosteroid use in this setting where most 
women have somewhat uncertain dates.  
Perspectives 
There has been increasing evidence for the role of time-of-disease maternal plasma PlGF in 
identifying incremental maternal and perinatal risks in pregnancies complicated by placental 
disorders (i.e, preeclampsia, fetal growth restriction and a large proportion of intrauterine fetal 
death), including in the similar settings in Maputo. To our knowledge, this is the first study to 
assess the impact of PlGF on clinical practice and outcomes in a less-developed country setting. 
We have identified that introducing PlGF into clinical care in antenatal clinics is associated with 
increased identification of women who are deemed to require transfer to higher levels of care. 
In addition, we have confirmed the ability of low PlGF, measured at time-of-disease, to identify 
women with pregnancies complicated by preeclampsia who are at increased risk of adverse 
events. Also, we have identified that a PlGF threshold of 40 – 50 pg/ml identifies a group of 
hypertensive pregnant women with a one-third risk of losing their fetus to stillbirth. This 
requires elucidation. This operational pilot provides additional insights to support the createion 
of a manual of procedures and recommendations for the scale up of the PlGF test to support 
the time-of-disease assessment of women with suspected preeclampsia, and screening for 
stillbirth risk, in high-risk pregnancies in Mozambique. 
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Highlights 
• In urban health centers in Mozambique, introducing PlGF for precision assessment of 
maternal risks increased referrals of women with preeclampsia to higher levels of care. 
• Low PlGF (<100 pg/ml) identifies women at increased risk of adverse maternal and 
perinatal events 
• Stillbirth complicates preeclampsia pregnancies approximately one-third of the time 
when PlGF <50 pg/ml. 
• All women in the study were hypertensive with suspected preeclampsia. 
• PlGF values were revealed to the clinical staff as an element of clinical assessment. 
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Figure legends 
Figure 1. (a) Time from clinic-to-delivery by placental growth factor concentration dichotomized 
between normal placental growth factor (≥100 pg/ml; median 10 days (blue)) and low placental 
growth factor (<99 pg/ml; median 36 days (red)). (b) Gestational age at delivery by placental 
growth factor concentration dichotomized between normal placental growth factor (≥100 
pg/ml; median 37 weeks) and low placental growth factor (<99 pg/ml; median 35 weeks). 
 
Figure 2. Area under the receiver operator curve for placental growth factor in predicting 
intrauterine fetal death (IUFD; purple) and perinatal mortality up to 28 days (PNM; blue). A 
maternal plasma placental growth factor concentration <41·8 pg/ml has 76·92% (95% 
confidence interval (CI) 60·67% - 88·87%) sensitivity, 78·2% (95% CI 72·5% - 83·3%) specificity, 
with a positive likelihood ratio (LR+) of 3·54 for intrauterine fetal death, and PlGF <39·7 pg/ml a 
66·7% (95% CI 52·1% - 79·2%) sensitivity, 79·7% (73·9% - 84·8%) specificity and LR+ of 3·29 for 
perinatal mortality. 
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Table 1. Baseline characteristics and outcomes (n (%) or median (interquartile range)) 
Characteristic Intervention sites P-value 
 PlGF ≥ 100 pg/mL 
(n = 148) 
PlGF < 100pg/mL 
(n = 130) 
 
Baseline characteristics 
Maternal age, yr 29 (24 – 34)  27 (22 – 31) 0·0061 
Nulliparous, Y 28 (18·9) 41 (31·5%) 0·0180 
Maternal weight, kg 70 (62 – 80) 
(n=146) 
71 (62 – 79) 
(n=127) 
0·6944 
Twin pregnancy, Y 2 (1·4%) 7 (5·4%) 0·0875 
Gestational age at recruitment, wk 30 (25 – 34) 33 (29 – 35)  0·0002 
Blood pressure at recruitment    
systolic blood pressure, mmHg 150 (142 – 162) 157 (146 – 172) 0·0004 
diastolic blood pressure, mmHg 94 (90 – 100) 101 (94 – 111) <0·0001 
Preeclampsia, Y 135 (91·2%) 130 (100%) 0·0002 
proteinuria ≥1+ 32 (21·6%) 67 (51·5%) <0·0001 
preeclampsia symptoms, Y 102 (74·9%) 112 (88·2%) 0·0021 
preeclampsia symptoms, n 1 (0 – 2) 2 (1 -3) <0·0001 
New diagnosis of HIV in this 
pregnancy, Y 
39 (21·3%) 30 (19·6%) 0·7865 
Serum PlGF, pg/mL 355 (186 – 828) 25·8 (≤12·0 – 58·9) <0·0001 
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Interventions received 
Number of prenatal visits, n 3 (1 – 4) 3 (2 – 5) 0·0006 
Antihypertensive(s), Y 122 (82·4%) 120 (92·3%) 0·0191 
Magnesium sulfate, Y 11 (7·4%) 12 (9·2%) 0·6650 
Antiretrovirals, Y 72 (48·6%) 77 (59·2%) 0·0917 
Dexamethasone, Y 1 (0·7%) 1 (0·8%) 1·0000 
Pregnancy outcomes 
Clinic-to-delivery interval, d 36 (11 – 83) 10 (1 – 25) <0·0001 
Gestational age at delivery, wk 37 (34 – 40) 35 (32 – 36) <0·0001 
Preterm birth, Y 81 (54·7%) 110 (84·6%) <0·0001 
Cesarean delivery, Y 41 (27·7%) 43 (33·1%) 0·3608 
Birth weight, kg 3·1 (2·7 – 3·4) 
(n=134) 
2·5 (2·0 – 3·0) 
(n=108) 
<0·0001 
Maternal mortality, Y 2 (1·4%) (missing = 
13) 
1 (0·8%) (missing 
=7) 
1·0000 
Perinatal and late neonatal mortality, 
Y 
14 (9·6%) 37 (28·5%) <0·0001 
intrauterine fetal death, Y 9 (6·1%) 30 (23·1%) <0·0001 
neonatal death <28d, Y 5 (3·6%) (n=139) 7 (7·0%) (n=100) 0·2475 
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Highlights 
• In urban health centers in Mozambique, introducing PlGF for precision assessment of 
maternal risks was associated with increased referrals of women with preeclampsia to 
higher levels of care. 
• Low PlGF (<100 pg/ml) identifies women at increased risk of adverse maternal and 
perinatal events 
• Stillbirth complicates preeclampsia pregnancies approximately one-third of the time 
when PlGF <50 pg/ml. 
• All women in the study were hypertensive with suspected preeclampsia. 
• PlGF values were revealed to the clinical staff as an element of clinical assessment. 
 
